While the possible collapse of the Treasury-bond market and the end of the global dollar financial system will certainly be catastrophic for many companies, there are still plenty of great businesses that will continue to provide goods and services and earn good profits.
In our democracy there’s a huge incentive for people to vote for benefits (money, credit, patronage) they do not have to pay for. These incentives create huge inefficiencies in our economy. Thus, Porter writes, it’s unlikely Elon Musk or anyone will be able to reduce government spending – and Social Security will disappear.
Stocks dropped 10% over a four-week period in February and March. As is usually the case, the performance of bonds didn’t capture quite as many headlines. But their behavior as equities sank is worth examining – especially by investors who don’t know about the benefits of distressed bonds.
Despite the risks and volatility in the U.S. stock market, there are many bargains emerging – if you know where to look. In this issue, we’re providing updates for six stocks in the portfolio that each trade at highly attractive valuations – and are being overlooked by Wall Street.
Dear Biotech Frontiers subscribers, I’m writing to you with two sell recommendations from the Biotech Frontiers portfolio this morning – one driven by good news, the other by bad. Let’s start with the good news. Last July, we recommended TG Therapeutics (Nasdaq: TGTX) with an entry price of $18.79 per share. We suggested that TG
Stocks in the S&P 500 are currently trading at sky-high valuations. With a weakening economy, it’s only a matter of time before share prices fall to levels at which valuation multiples decline to historical averages.
Today we look at the key vulnerability facing the U.S. economy: the end of the wealth effect created from the greatest bull market of the last 50 years, and how it removes a key pillar of strength holding up the U.S. economy.